Role of extent of resection for the surgical outcome in low-grade oligoastrocytoma: a case study


  • Dipak Chaulagain Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
  • V. Smolanka Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
  • A. Smolanka Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
  • T. Havryliv Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine



oligoastrocytoma, astrocytoma, glioma, extent of resection


Oligoastrocytoma (OA) is a part of the glial cell continuum, which also includes astrocytes and oligodendrocytes. As defined by the World Health Organization, this type of tumor is considered low-grade (grade II). Oligodendroglioma and oligoastrocytoma are both diffusely infiltrating, slow-growing gliomas having oligodendroglial or astrocytic cell architecture. Essentially, the surgical outcome in OA depends on the amount of tumor removed during surgery, its location, the patient’s age, and the extent to which postoperative radiation and/or chemotherapy were used. The concept of the amount of tumor excision and its impact on the surgical outcome in OA patients is considered. The subject of this study is a 30-year-old man who had a history of seizures and was diagnosed with OA. He underwent OA excision at the Regional Clinical Center of Neurosurgery and Neurology in Uzhhorod, Ukraine. Using intraoperative neuromonitoring, surgeons were able to do a 63.5% excision of the tumor followed by chemotherapy. As a result, the patient became seizure-free in the follow-up period. The case study highlights the critical nature of surgical resection and subsequent chemotherapy in the treatment of low-grade oligoastrocytoma. In certain individuals, a gross or subtotal surgical approach may significantly decrease tumor volume, hence favoring future treatment. As a result, such a combination should be regarded as a means of delaying radiation and improving the quality of life. Additional research is necessary to identify patients who respond well to treatment.


Download data is not yet available.


Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Bur-ger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007. 114. 97-109.

Louis D.N., Perry A., Reifenberger G., von Deimling A., Fi-garella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016. 131. 803-820.

Von Deimling A., Refeinberger G., Kros J.M. et al. Oligoastrocytoma. In: Luois D.N., Oghaki H., Wiestler O.D., Cavenee W.K., eds. WHO classification of tumors of the central nervous system. Lyon: IARC Press; 2007. 63-66.

Jiao Y., Killela P.J., Reitman Z.J. et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012. 3. 709-22.

Sahm F., Reuss D., Koelsche C. et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014. 128. 551-9.

Wiestler B., Capper D., Sill M. et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014. 128. 561-71.

Hewer E., Vajtai I., Dettmer M.S. et al. Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas. Histopathology. 2016. 68. 272-8.

Berger M.S., Deliganis A.V., Dobbins J.D., Keles G.E. The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer. 1994. 74. 1748-1791.

Duffau H., Lopes M., Arthuis F., Bitar A., Sichez J.P., Van Effenterre R., Capelle L. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985–1996) and with (1996–2003) functional mapping in the same institution. J. Neurol. Neurosurg. Psychiatry. 2005. 76. 845-851.

Keles G.E., Lamborn K.R., Berger M.S. Low grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg. 2001. 95. 735-745.

Smith J.S., Chang E.F., Lamborn K.R., Chang S.M., Prados M.D., Cha S., Tihan T., Vandenberg S., McDermott M.W., Berger M.S. Role of extent of resection in the long-term outcome of low grade hemispheric gliomas. J. Clin. Oncol. 2008. 26. 1338-1345.

Reifenberger G., Kros J.M., Burger P.C., Louis D.N., Collins V.P. Oligoastrocytoma. In: Kleihues P., Cavenee W.K., eds. Tumours of the nervous system. Lyon, France: IARC Press; 2000. 65-67.

Behin A., Hoang-Xuan K., Carpentier A.F., Delattre J.Y. Primary brain tumours in adults. Lancet. 2003. 361. 323-331.

Olson J.D., Riedel E., DeAngelis L.M. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000. 54. 1442-1448.

Beckmann M.J., Prayson R.A. A clinicopathologic study of 30 cases of oligoastrocytoma including p53 immunohistochemistry. Pathology. 1997. 29. 159-164.

Ricci P.E., Dungan D.H. Imaging of low- and intermediate-grade gliomas. Semin. Radiat. Oncol. 2001. 11. 103-112.

Shaw E.G., Scheithauer B.W., O’Fallon J.R., Davis D.H. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery. 1994. 34. 577-582.

Chaulagain D., Smolanka V.I., Smolanka A.V., Havryliv T.S. The impact of extent of resection in surgical outcome of pilomyxoid astrocytoma: a case study. Ukrainian Neurosurgical Journal. 2021. 27(4). 43-48.

Klein M., Heimans J.J., Aaronson N.K., van der Ploeg H.H.M., Grit J., Muller M., Postma T.J., Mooij J.J., Boerman R.H., Beute G.N., Ossenkoppele G.J., van Imhoff G.W., Dekker A.W., Jolles J., Slotman B.J., Struikmans H., Taphoorn M.J. Effect of radiotherapy and other treatment related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002. 360(9343). 1361-1368.

Chaulagain D., Smolanka V., Smolanka A. Intracranial tumors: overview, histological types, symptoms and treatment plans. Int. J. Health Sci. Res. 2021. 11(10). 133-144.

Brada M., Viviers L., Abson C., Hines F., Britton J., Ashley S., Sardell S., Traish D., Gonsalves A., Wilkins P., Westbury C. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. 2003. 14. 1715-1721.

Buckner J.C., Gesme D. Jr, O’Fallon J.R., Hammack J.E., Stafford S., Brown P.D., Hawkins R., Scheithauer B.W., Erickson B.J., Levitt R., Shaw E.G., Jenkins R. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 2003. 21. 251-255.

Mason W.P., Krol G.S., DeAngelis L.M. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996. 46. 203-207.

Soffietti R., Ruda R., Bradac G.B., Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998. 43. 1066-1073.

Pace A., Vidiri A., Galie E., Carosi M., Telera S., Cianciulli A.M., Canalini P., Giannarelli D., Jandolo B., Carapella C.M. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 2003. 14. 1722-1726.

Wessels P.H., Weber W.E., Raven G., Ramaekers F.C., Hopman A.H., Twijnstra A. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003. 2. 395-403.




How to Cite

Chaulagain, D., Smolanka, V., Smolanka, A., & Havryliv, T. (2022). Role of extent of resection for the surgical outcome in low-grade oligoastrocytoma: a case study. INTERNATIONAL NEUROLOGICAL JOURNAL, 18(2), 10–14.



To practicing Neurologist

Most read articles by the same author(s)